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Abstract: Cancer mortality rates are undergoing a global downward trend; however, metastasis and
relapse after surgery and adjuvant treatments still correlate with poor prognosis and represent the
most significant challenges in the treatment of this disease. Advances in genomics, metabolomics,
and proteomics are improving our understanding regarding cancer metabolic diversity, resulting
in detailed classifications of tumors and raising the effectiveness of precision medicine. Likewise,
the growing knowledge of interactions between nutrients and the expression of certain genes could
lead to cancer therapies based on precision nutrition strategies. This review aims to identify the
recent advances in the knowledge of the mechanistic role of bioactive phytochemicals in foodstuffs in
tumor progression, metastasis, and chemo-resistance in order to assess their potential use in precision
nutrition therapies targeting relapse in lung, breast, colon, and prostate cancer, and leukemia.
A considerable number of bioactive phytochemicals in foodstuffs were identified in the literature
with proven effects modulating tumor growth, progression, and metastasis. In addition, the use of
foodstuffs in cancer, and specifically in relapse therapies, is being reinforced by the development
of different formulations that significantly increase the therapeutic efficiency of these products.
This can open the possibility for testing combinations of bioactive phytochemicals with cancer relapse
treatments as a potential prevention strategy.
Keywords: precision nutrition; cancer relapse; bioactive phytochemical foodstuffs; lung; breast;
prostate; colon; leukemia
1. Introduction
1.1. Breast, Colon, Lung, Prostate and Leukemia: The Deadliest Cancers
Lung, breast, prostate, and colon cancers have the highest overall incidence and represent 36.4%
of the total diagnosis according to GLOBOCAN 2018, a report that gathers data from the International
Agency for Research on Cancer of the World Health Organization [1]. Besides their high occurrence,
these types of cancer add up to a mortality rate that reaches 49.2% of the diagnosed cases. In addition,
blood malignancies count with a rate of 6.5%, an incidence particularly worrying as it is the highest in
children and young adults.
In the last five years international scientific production related to new basic and translational
discoveries on cancer has grown by 5% annually. Lung, colon, breast, prostate, and leukemia cancers
account for 51% of scientific publications on cancer in this period (Web of Science, Clarivate Analytics,
Philadelphia, PA, USA). Many papers address the association between gene regulation and cancer
progression or metastasis, still representing the main approach in cancer research. More recently,
an increasing number of investigations based on genomics and epigenomics are focusing on the
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improvement of tumor classification, the relationship between cancer and microbiota, or the discovery
of new therapeutic targets in metabolism, in order to develop specific therapies in the context of
precision medicine.
1.1.1. Lung Cancer
Survival is the foremost concern in lung cancer due to its progressive metastasis and resistance to
therapy and, furthermore, the molecular hallmarks of its malignant properties are still insufficiently
known. Recently, a 17-gene panel involving critical cellular processes such as hypoxia-mediated
epithelial-mesenchymal transition (EMT) or epigenetic modifications was identified as a potential
biomarker tool for prediction of metastasis and prognosis in patients affected by non-small-cell lung
cancer (NSCLC) [2]. Other example of the last advances in this field is the detection of the scaffold
WT1-interacting protein (WTIP) as a novel tumor suppressor down-modulated in NSCLC. Lower levels
of these proteins significantly correlate with poor prognosis as a result of higher rates of cell proliferation
and tumorigenesis [3]. Additionally, increasing findings in immunotherapy open expectations for the
improvement of the prognosis of lung cancer patients [4].
1.1.2. Breast Cancer
Regarding breast cancer, tumor heterogeneity makes patient classification according to their risk
of metastatic relapse essential in order to guide decisions in adjuvant chemotherapy. However, in the
era of personalized medicine, genomics alone does not provide enough knowledge to apply precision
treatments to specific tumors. Therefore, complementary multi-omic studies are emerging as the
most promising approaches addressing breast cancer complexity [5]. For instance, a quantitative
proteotyping approach based on sequential windowed acquisition of all theoretical fragment ion
spectra mass spectrometry (SWATH-MS) has been proposed to establish key proteins for breast tumor
classification [6].
1.1.3. Prostate Cancer
The application of new technologies now allows progressing in the understanding of the molecular
basis of prostate cancer pathogenesis. Microarray-based transcriptomic analyses and next generation
sequencing technology are examples of powerful tools for studying gene expression and changes
in gene structure at the transcript level. Recent publications described new mechanisms regarding
tumor suppressors in this type of tumors [7] and new potential therapeutic targets [8]. Also, these
technologies played a critical role in recent studies indicating specific gene fusions, present in at
least 50% of prostate tumors, as key modulators of gene expression promoting tumor growth and
progression in prostate cancer [9].
1.1.4. Colorectal Cancer
Deregulated cellular energetics is another of the hallmarks of cancer. In this sense, cooperative
lipid metabolism-related genes involved in colorectal cancer progression have been recently identified.
The acyl-CoA synthetase/stearoyl-CoA desaturase (ACSL/SCD) lipid network fuels migratory and
invasive properties through EMT induction and is associated with an increased risk of relapse in
colorectal cancer patients [10]. Other molecular mechanisms associated with the refractory nature of
cancer point to cancer stem cells (CSCs). In this regard, it has been recently published that proliferation
of CSC-enriched colon spheroids is dependent on mTORC1 kinase, which is activated by reactive
oxygen species (ROS) produced by an NADPH oxidase [11]. Furthermore, the potential correlation
between gene polymorphisms and colon cancer progression continues being studied and validated in
order to identify prognostic indicators supported by mechanisms such as the increased invasiveness of
tumor cells through the expression of genes involved in the activation of fatty acids through conversion
to acyl-CoA [12], or the regulation of COX2 expression and cell apoptosis [13]. On the other hand,
it has been recently discovered that microbiota plays an important role in colorectal carcinogenesis.
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This opens up new opportunities for using microbiota profiling information in colorectal cancer
prevention, diagnosis, and therapy [14].
1.1.5. Blood Malignancies
Recent advances in leukemia genomics and epigenomics have facilitated the study of clonal
populations and their genetic-epigenetic evolution, changing the classic view of leukemia into a
complex heterogeneous disease aggravated by clonal evolution [15,16]. These findings allow a better
understanding of the mechanisms involved in leukemia transformation and therapy resistance and
reinforce precision medicine as the most promising approach to leukemia treatment. The complexity
of this disease, together with the high number of patients showing chemotherapy resistance, evidences
the urgent need of more efficient therapies. In the last years, new therapeutic approaches are being
investigated, as for instance monoclonal antibodies-based treatments [17] or therapies based in
macrophage targeting [18].
1.2. Cancer Relapse
Cancer relapse worsens the prognosis of patients and is a factor that contributes significantly to
mortality. However, only 2% of cancer publications in the last five years deal specifically with relapse
(Web of Science, using databases including MEDLINE). Cancer recurrence involves many biological
interactions, such as genetic, transcription, environmental, endocrine signaling, and metabolism.
These interactions add another layer of complexity in the understanding of cancer recurrence and
metastasis, delaying progress in therapeutic opportunities [19]. Lung cancer and leukemia mortality
rates are mainly due to their higher recurrence rates, compared to breast, colon, and prostate, for which
surgical resection of the tumor combined with adjuvant treatments accomplish higher survival rates [20].
Lung cancer has a recurrence rate that reaches 50% of patients. Despite having noteworthy
advances in recent years on the knowledge of the disease biology and mechanisms of tumor progression,
the survival rates remain low and more research is necessary on molecular aspects that give rise to
more effective therapies [21]. Discovering the association of gene expression with recurrence is of
utmost interest in order to develop therapies to prevent and treat relapse [22]. For example, it has
recently been identified that the long non-coding RNA AWPPH over-expression is involved in NSCLC
recurrence by the upregulation of TGF-b1, finally increasing cancer cell migration and invasion [23].
In respect of leukemia, the high number of relapse-specific mutations acquired by patients affecting
genes involved in different functions, leading to clonal evolution and resulting in chemotherapy
resistance, points to the high molecular complexity of this process [24,25]. Understanding the role of
relapse-specific mutations will foster the development of new therapies for the treatment of high-risk
patients. In recent years, several groups have dealt important advances in the knowledge of these
mutations using whole-genome sequencing technology in leukemia patient samples. For instance,
mutations in the phosphoribosyl pyrophosphate synthetase 1 gene (PRPS1), encoding a purine
biosynthesis enzyme, were associated a few years ago with chemotherapy resistance and relapse [26].
In addition, the role of the cytosolic 5’-nucleotidase cytosolic II gene (NT5C2) has recently been
described regarding clonal evolution and chemotherapy resistance, with important implications in the
development of new targeted inhibition therapies [27,28].
In essence, the recent discoveries in relation to drug resistance and previously unknown molecular
mechanisms associated with metastasis and recurrence demand alternative therapeutic strategies,
among which metabolism could emerge as a new cancer therapy support. Although cancer relapse is
due to a multitude of genetic mutations and biochemical processes, advances in genomics, metabolomics,
and proteomics allow better understanding of the metabolic diversity due to genetics and microbiome
variation, as well as a detailed classification of tumors, which provide precision medicine with
individual treatments. Likewise, the best understanding of the metabolic variation allows us to
know the interactions between nutrients, metabolism, microbiota, and related genes, facilitating the
development of adjuvant cancer therapies based on precision nutrition strategies [29].
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1.3. Precision Nutrition and Cancer Therapy
Over the years, numerous epidemiological studies have been carried out to link the diet with
cancer, either from a preventive approach or by associating the consumption of certain food products
with tumor generation and growth. However, in parallel to the development of precision therapies
in medicine, precision nutrition is an emerging science that relies on well-established factors such
as genetic and epigenetic variation [30] and the microbiome [31]. It has recently been shown that
the treatment of human cell lines with different bioactive foodstuffs influences their physiological
attributes depending on their ability to influence the expression of different genes [32]. The possibility
of using nutritional therapies against cancer, as a complementary medicine, is internationally accepted
due to its advantages of less toxicity and better acceptance by patients [33]. In the case of breast
cancer, complementary phytochemical therapy in adjuvant treatments has been proposed both with
preventive effects and during conventional treatments after diagnosis [34], concluding that nutritional
strategies can be effective for prevention of relapse [35].
Epidemiological studies triggered further research in terms of molecular mechanisms, which have
significantly improved the effectiveness of phytotherapy, entering the context of precision nutrition [36].
Recent studies on the association between prevention, treatment, and recurrence of cancer suggest the
benefit of investigating the link between specific food components and certain health outcomes [37].
Since very specific therapeutic targets must be reached, precision nutrition must be based on individual
foodstuffs with well-established mechanisms of action at the molecular level in terms of gene expression
modulation and signaling pathways involved in proliferation, invasion, angiogenesis, and metastasis or
apoptosis [38]. For example, it has been shown that it is possible to attack genetic instability associated
with cancer through nutritional strategies that inhibit proliferative signaling, attenuate oncogenic
metabolism, and block inflammation [39].
The biological activity of food polyphenols, a broad family of compounds with representatives
in virtually all foods, has been specially studied for decades since they have in common an intense
antioxidant activity that suggests other potential health outcomes, for example in breast cancer [40].
Recently, intensive research has been carried out to determine the preventive or therapeutic activity
of different natural phenolic compounds [41], opening ways for its application in new treatments
of various types of cancers such as breast [42–45], colon [46], or prostate [47,48]. Some synthetic
phenolic compounds have also been successfully studied for the treatment of some cancers [49].
In addition to polyphenols, curcumin (diferuloylmethane) is one of the most studied foodstuffs in
recent years as a potential therapeutic product for cancer and more specifically for leukemia [50].
Traditional food products, such as rosemary extract, have been proposed as potential ingredients of
precision nutritional supplements in cancer therapy, identifying molecular mechanisms related to the
effects and the interactions with currently-used anticancer agents [51]. In the case of colorectal cancer,
lipid-metabolism-related genes have acquired relevant interest for precision nutrition therapies, since
a wide range of tumorigenic steps can be influenced by lipid metabolism, both in primary tumors and
distal metastasis [52]. Certain therapeutic strategies based in diet patterns during adjuvant treatments
are also sometimes considered as precision therapies [53]. Finally, multi-targeting profiles of food
ingredients are being investigated regarding their potential roles triggering anti-cancer molecular
mechanisms through the modulation of certain gene expressions or signaling pathways [54].
The objective of this review is to identify the recent advances in the knowledge of mechanisms
that support the effects of bioactive phytochemicals in foodstuffs associated with molecular targets
of tumor progression, metastasis, or chemo-resistance, in order to assess the potential use of these
products in precision nutrition therapies addressing the prevention of relapse in lung, breast, colon,
and prostate cancer, and leukemia.
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2. Material and Methods
2.1. Systematic Search
A literature search was carried out on September 30th 2019 in Web of Science using the following
databases: Web of Science Core Collection (WOS), Current Contents Connect (CCC), Derwent
Innovations Index (DIIDW), Korean Journal Database (KJD), MEDLINE, Russian Science Citation
Index (RSCI) and Scientific Electronic Library Online (SCIELO). In order to capture only the most
recent advances, articles published between 2017 and 2019 were considered. The language filter was
English. The same search strategy was carried out in SCOPUS. PUBMED was not used since it is a
search engine in MEDLINE, already included in WOS.
Search a strategy included three layers of keywords: (1) types of cancer targeted; (2) the most
studied bioactive foodstuffs in the literature cited in the introduction, together with keywords indicating
the characteristic factors of precision nutrition; (3) keywords identifying cancer relapse trying to cover
all synonyms. In order to open the search, asterisk-terminated keywords were introduced. The search
for the first indicator (the five target types of cancer) was performed on the “title” field of the search
engine. However, the search for the second indicator, the one related to bioactive foodstuffs and the
third one related to cancer relapse and its synonyms, were searched in the “topic” field, which includes
title, keywords, and abstract; in order to include all types of research approaches. The keywords were
combined using boolean operators “AND”, “OR”. The detailed search strategy is presented in Table 1.
Table 1. Search Strategy.
Field Keywords Boolean Operator
Title
((cancer* OR carcino* OR tumor* OR
tumour* OR onco*) AND (lung* OR
breast* OR mammar* OR colon* OR
colorect* OR prostat* OR leuk*))
AND
Topic (title, keywords, abstract)
((phytochem* OR polyphen* OR flavon*
OR gallate* OR catechin* OR omega* OR
DHA OR docosahexaenoic* OR terpen*
OR curcum* OR extract*) AND (gen* OR
genetic* OR genomic* OR microbio*))
AND
Topic (title, keywords, abstract)
(relapse* OR recurrence* OR
reappearance* OR replication* OR
repetition* OR return* OR reemergence*)
By using prefixes ending in an asterisk, a greater opening of the search is achieved, since keywords are identified
more securely even if they end with different plurals or suffixes.
The first field included general descriptors of cancer and its scope before “AND”. The second
part identified the five types of cancer that are the subjects of this review. The first part of the
second field included keywords on bioactive foodstuffs associated in the literature to positive effects
on tumor progression or metastasis: Phytochemicals and plant extracts, phenolic compounds of
various chemical structures, omega-3 polyunsaturated fatty acids (mainly docosahexaenoic acid
(DHA)), and curcuminoids that are being studied in the field of cancer therapies in recent years [55,56].
The second part includes prefixes of concepts that cover the main mechanistic characteristics of precision
nutrition studies such as genes, genetics and epigenetics, genomics, microbiota, and microbiome.
The third field comprises different denominations of cancer relapse.
2.2. Inclusion Criteria
Publications that met the criteria of the search strategy were downloaded in full text and reviewed
by the authors. Articles referring to dietary indices for prognosis, epidemiological studies, articles
without identification of the specific molecules of the products studied, articles related to food
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Figure 1 shows the flow diagram of the search and article selection process. The search in WOS
provided 303 results, while the search in SCOPUS contributed 271. All the articles obtained from
SCOPUS were included among the WOS retrieved. In consequence, 303 was the number of records
remained after removing the duplicate articles. Full texts of the 303 initially identified papers were
revised to assess their eligibility. Literature review articles, epidemiology studies, and papers referring
to diets or nutrient groups were excluded. As a result of this revision, 35 articles on phytochemicals or
bioactive foodstuffs, containing mechanistic descriptions of their effects on tumor growth, progression,
metastasis or, more specifically, relapse, were finally included for qualitative synthesis.
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3.2. Characteristics of Included Studies
In the initial screening of titles, abstracts, and keywords, no records were excluded since the 303
identified papers met the search criteria. However, th strict evaluation of th full-text articles revealed
that most of them did not contain adequate studies for the purpose of this review. Consequently,
just over 10% of the papers identified were included for qualitative synt esis. Only research pap rs
Nutrients 2019, 11, 2799 7 of 20
including molecular mechanistic knowledge were accepted, according to the objective of this review.
Nevertheless, certain research on well-characterized bioactive extracts of plant, fruits, vegetables were
also accepted although they did not include new mechanistic contributions.
3.3. Outcome
Twenty of the original research studies finally selected for qualitative analysis dealt with polyphenol
foodstuffs, and three with lipids, mainly omega-3 and more specifically DHA. In addition, 12 articles on
bioactive plant extracts were identified. Table 2 shows, categorized by types of compounds, the main
characteristics of the articles that study the molecular mechanisms of individual bioactive foodstuffs
with relevance in cancer relapse.
Table 2. Characteristics of included studies related to polyphenol foodstuffs. Results are alphabetically
sorted by bioactive foodstuff. Molecular mechanisms are summarized indicating inhibition (↓) or
activation (↑) regarding either gene expression, signaling pathways, protein stability, or protein
post-translational modifications. Regulated targets are shown in italics.
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All compounds in Table 2 are frequently-used food products of which safety and bioactivity
have been extensively studied. Overall, these products synergize with chemotherapy treatments by
affecting routes associated with cell proliferation, migration or invasion, or by activating apoptosis.
Altogether, these effects result in tumor growth repression, finally contributing to cancer remission and
relapse prevention.
Regarding research on anticancer effects of food extracts, the knowledge of mechanisms of action
is far more limited compared to polyphenol foodstuffs, due to the integration of several compounds in
each extract. Despite this, they have been considered in this study since they may tentatively constitute
ingredients of nutritional supplements for the treatment of different cancers. Table 3 summarizes
the anticancer effects and features of food extracts with known molecular mechanisms included in
this review.
Table 3. Characteristics of included studies related to bioactive natural extracts.
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Table 3. Cont.
Extract Source Bioactive Fraction Cancer Type Molecular Mechanism Anticancer Effect Reference
Ginseng Ginsenoside Rg3 Colorectal
Cell survival inhibition
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3.4. Nanotechnology and Precision Nutrition for Cancer
The inclusion of natural bioactive foodstuffs in therapies for different types of cancers is increasingly
being accepted in the clinical setting. Potentiating the use of these bioactive compounds in cancer
treatment requires improving its bioavailability. Therefore, a significant activity formula development
is being carried out in this regard. In this sense, the case of curcumin stands out, since it is one of
the most studied bioactive foodstuffs in terms of its potential anticancer effect. Various curcumin
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nano-preparations have recently been developed. Table 4 shows the latest published works on curcumin
nano-formulations that have shown superior antitumor activities than the pure bioactive product.
Table 4. Curcumin nano-formulations.
Bioactive
Foodstuff Cancer Type Nano-formulation Molecular Mechanisms Anticancer Effect Reference
Curcumin Breast H-ferritin (HFn)nanoparticle
HFn biopolymer
specifically binds to the
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Formulations aiming to increase the bioavailability of bioactive natural foodstuffs are essential
for the application of these products in cancer therapies since, as we have seen, most of the
phytochemicals reviewed in this work are generally hardly bioavailable polyphenols. Development
of new nano-formulations of bioactive foodstuffs is key to widespread use of these products in
cancer therapy.
4. Discussion
Since the same factors that are successfully driving precision medicine in cancer serve to design
precision nutritional therapies, it is foreseeable that a new era in the treatment of cancer can be opened
in coming years. Integration of nutritional strategies may be of special interest for patients treated with
adjuvant therapy, in order to enhance therapy effects and to prevent cancer relapse. The knowledge
regarding several bioactive foodstuffs mechanisms of action, and the fact that most of them address
well established molecular targets, allows the transition into a potential clinical use. In the last decade,
a growing number of research works have investigated the anticancer effects of bioactive natural
products. However, only very recently have the molecular mechanisms by which nutrients may
prevent relapse been explored.
Table 2 includes a list of bioactive food compounds identified in the literature review, and the
molecular mechanisms of their anticancer effects. Polyphenols have been the most studied family
of compounds in decades for their different biological activities. In addition, some flavonoids have
recently shown antitumor and antiproliferative activities that can be useful in relapse-preventive
treatments. Epigallocatechin-gallate (EGCG), a flavonoid present in green tea, has been shown to
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inhibit tumor cell growth and increase apoptosis, promoting tumor suppression. This compound
sensitizes human colon cancer cells to 5-fluorouracil, increasing the effects of adjuvant treatment and
improving prognosis, and finally reducing tumor relapse risk [68]. EGCG can also prevent lung cancer
relapse in lung cancer mouse xenografts by blocking the cancer stem-cells-like growth through the
modulation of the hsa-mir-485-5p/RXRα axis and downregulating protein acetylation in lung carcinoma
cells [65,66]. EGCG has been also been predicted to affect several pathways involved in cell death
and survival, potentially leading to a reduced cancer progression [67]. However, further molecular
validations are needed in this sense. Another flavonoid with interesting features for relapse prevention
is quercetin, which is present in vegetables such as onions. Quercetin promotes apoptosis and
inhibits cell proliferation by modulating important signaling targets as PI3K/Akt or NF-κB effectively
eliminating prostate CSCs. It also limits cell migratory capacity and progression of prostate cancer cell
lines by the downregulation of MK [71]. In breast cancer, quercetin can help preventing relapse by
decreasing expression and activation levels of mTOR, PI3K and Akt proteins leading to a significant
inhibition of MCF7 cancer cell proliferation [72]. Another flavonoid with potentially interesting effects
for the development of precision nutrition products is apigenin, present in fruits, vegetables, and
food herbs such as parsley. This compound improves the effectiveness of adjuvant therapy with
cisplatin enhancing both cytotoxicity and its anti-migratory effect on prostate cancer stem cells [57].
Apigenin also helps preventing metastasis and relapse in non-small cell lung cancer cell lines and in
an in vivo orthotopic bioluminescent xenograft model by inhibiting cell migration and invasion [58].
Other interesting flavonoids are naringenin, obtained from citrus peel, which has been shown to inhibit
proliferation and to induce apoptosis in prostate cancer cells [69], and procyanidin-B2-3,3”-di-O-gallate
(B2G2) extracted from grape seeds, that targets both differentiated cells and CSCs leading to tumor
mass reduction [70].
Curcumin is another bioactive food product that has been the subject of former numerous studies.
Its anti-cancer effects, due its ability to modulate critical anti-apoptotic effectors such as Bcl-xl and
NF-κB, are of prominent interest in potential relapse prevention treatments. Moreover, curcumin
synergizes with vesicular stomatitis virus (VSV)-based oncolytic treatments modulating antiviral
responses and components of the intrinsic apoptotic pathway in a prostate cancer cell model [59].
Furthermore, in colorectal cancer, curcumin can modulate gene expression of HSPA5, SEC61B, G6PD,
HMOX1, and PDE3B, affecting essential pathways like DNA replication or the cell cycle. On the other
hand, the synergy of curcumin and oligomeric proanthocyanidins emerges as an opportunity to develop
effective therapies, since both compounds share similar molecular mechanisms [60]. Recently, relevant
effects of curcumin in breast cancer cell models have been discovered, being that this compound is able
to increase the expression of E-cadherin and decrease the expression of mesenchymal markers [61].
It has been also shown that curcumin enhances the effect of some targeted drugs used in cancer such
as gefitinib, an EGFR inhibitor, inducing autophagy-mediated apoptosis. This observation opens up
opportunities for the use of this compound with treatments to prevent cancer relapse [62].
Some lipid character food bioactives also show anti-cancer effects with mechanisms of action
interesting for cancer relapse prevention. In this sense, docosahexaenoic acid (DHA) modulates the
growth of colorectal cancer cells and induces expression of genes related to apoptosis [63,64]. Also,
β-sitosterol-d-glucoside has inhibitory effects on breast cancer cells growth [74].
The studies mentioned above explain many of the effects on cell growth, tumor progression
and metastasis of food bioactive products, opening promising opportunities for the application of
these phytochemical foodstuffs in therapies for cancer relapse in breast, prostate, lung, and colon
cancer. However, no studies of individual food products were found that applied to leukemia
relapse. Regarding this type of cancer, only one paper was recovered, suggesting that additional
research should be made in this sense. The cited article analyses the effects of a ginger extract rich in
gingerols, demonstrating that this extract exerts a synergistic interaction with methotrexate with high
antiproliferative impact in the drug-resistant leukemic sub-lines [78]. Nevertheless, the mechanism
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that supports this effect is not explained. Indeed, the same happens with other food extracts recently
studied and would require additional studies.
Table 3 shows the publications on natural extracts identified in the bibliographic search.
In general, interesting antitumoral, antiproliferative, or antimetastatic effects are demonstrated,
however, the molecular mechanisms concerning these effects remain largely unknown in most cases.
An exception may be the grape seed extract, rich in proanthocyanidins associated with antitumor
effects in colorectal cancer in combination with curcumin, by regulating cell cycle and migration [80].
Other extracts with identified effects on cell growth, tumor progression and metastasis in colorectal
cancer are watercress extract, rich in phenethyl isothiocyanate [86]; ginseng extract, rich in ginsenoside
Rg3 [79]; and isodon extract, rich in flexicaulin A [81]. Importantly, orange peel extract, rich in
nobiletin, sinensetin, scutellarein tetramethylether, and tangeretin, exerts a synergistic interaction
with 5-fluorouracil in colorectal cancer, modulating EMT transition, inhibiting cell proliferation and
modulating cancer stemness, demonstrating a significant potential use of this combination in relapse
preventive therapies [82]. In any case, further research needs to be done in order to identify molecular
mechanisms regarding the effects of these extracts. Although only individual compounds are now
useful in precision nutritional strategies against well-identified therapeutic targets, these studies allow
considering the extracts as an intermediate step towards the purification of the specific component
responsible for the observed effect. In addition, the low toxicity of these extracts makes them suitable
for other support therapies as nutritional supplements.
One of the barriers to be overcome in the application of bioactive phytochemical foodstuffs
in cancer therapies is the frequent lack of bioavailability of these products. In this sense, new
formulation strategies are being developed, such as bioactive carrier lipids in which the carrier not only
increases bioavailability, but also provides a synergistic biological activity with the active ingredient.
Interestingly, it has been reported that the use of shark liver oil rich in alkylglycerols as a bioactive
lipid vehicle for rosemary extract shows synergistic effects in the expression of genes associated
with immune modulation, inflammation, oxidative stress, lipid metabolism, and tumorigenesis in
colorectal cancer [84]. Besides this, a good example of a non-soluble and instable product is curcumin.
This compound is emerging as a potent effector acting on numerous signaling and molecular pathways
that regulate tumor growth and cancer relapse. Despite the growing knowledge about its properties,
curcumin cannot be approved as a therapeutic compound due to its limitations in terms of bioavailability
and stability. Regarding this, several formulation studies are being performed and a significant number
of cases have provided better therapeutic results than the individual bioactive [87–91].
5. Conclusions
Although, in the context of cancer research, studies that refer to nutritional therapies based on the
use of bioactive foodstuffs in adjuvant treatments are still limited, current results are encouraging since
there are several phytochemical bioactive foodstuffs with proven modulating effects of tumor growth,
progression, and metastasis, and therefore can be tested in humans with a reasonable probability
of success if they are applied in cancer relapse treatments (Figure 2). In this sense, the compounds
currently identified for this purpose are in general extensively-studied products in the last years
such as the polyphenols apigenin, epigallocatechin gallate, procyanidin B2-3,3-di-O-gallate, quercetin,
naringenin, secoisolariciresinol diglucoside, and curcumin, as well as docosahexaenoic acid and
β-Sitosterol-d-glucoside lipids. Among the targeted cancers included in this review, lung and colon
cancer are being widely studied, and prostate and breast cancer have concentrated the largest number
of applications. However, there is a great lack of studies related to the use of phytochemical foodstuffs
in leukemia therapies and more studies are needed in this disease. The possibilities of using foodstuffs
in cancer treatments and more specifically anti-relapse therapies, are being reinforced with the
development of formulation technologies that significantly increase the efficiency of these products.
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Cancer heterogeneity is one of the features of this disease that makes its treatment particularly
challenging. Innovative therapies for patients are continuously being tested and progress has been
made in the last years developing early diagnosis protocols and improving patient prognosis. However,
despite these efforts, a high percentage of patients relapse after surgery or initial therapy. Cancer relapse
involves a great number of different molecular mechanisms that vary form one patient to another.
This points to precision medicine as a key element to personalize cancer treatment and prevent relapse,
and suggest the value of new effective and safe compounds that potentiate the effects of already-known
chemotherapy agents. In this sense, the growing number of studies regarding the mechanisms of
several bioactive foodstuffs in the treatment of different types of cancer, open a new layer in precision
cancer therapy. Its association with specific genetic targets or different molecular pathways inhibiting
tumor growth and metastasis constitutes an important customization component. Moreover, it shows
high synergism with several chemotherapy drugs, acting as enhancers of these anti-tumor effects or
even sensitizing and reverting chemotherapy resistance. In essence, these products are emerging as
novel complementary agents that can be useful in precision nutrition therapies addressing relapse
prevention in treatments of cancerous processes.
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